Seven Fleet Capital Management LP Buys 232,926 Shares of Savara Inc. $SVRA

Seven Fleet Capital Management LP lifted its position in Savara Inc. (NASDAQ:SVRA) by 371.1% in the first quarter, Holdings Channel reports. The firm owned 295,688 shares of the company’s stock after buying an additional 232,926 shares during the period. Seven Fleet Capital Management LP’s holdings in Savara were worth $1,614,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of SVRA. Swedbank AB lifted its holdings in shares of Savara by 54.5% in the 4th quarter. Swedbank AB now owns 850,000 shares of the company’s stock worth $5,126,000 after buying an additional 300,000 shares during the period. F m Investments LLC increased its stake in shares of Savara by 56.5% during the fourth quarter. F m Investments LLC now owns 678,813 shares of the company’s stock valued at $4,093,000 after buying an additional 245,100 shares during the period. Nan Fung Trinity HK Ltd. purchased a new position in shares of Savara during the fourth quarter valued at $10,182,000. Orbimed Advisors LLC bought a new stake in shares of Savara in the first quarter valued at about $3,467,000. Finally, Eversept Partners LP bought a new stake in shares of Savara in the fourth quarter valued at about $1,026,000. Institutional investors own 87.93% of the company’s stock.

Savara Trading Down 1.4%

Shares of NASDAQ SVRA opened at $5.46 on Friday. The business has a fifty day moving average price of $5.58 and a 200 day moving average price of $5.51. Savara Inc. has a 1-year low of $2.43 and a 1-year high of $7.01. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. The stock has a market capitalization of $1.12 billion, a P/E ratio of -9.75 and a beta of 0.24.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Equities research analysts expect that Savara Inc. will post -0.57 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. Finally, Oppenheimer initiated coverage on shares of Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.14.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.